Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 16, 2022; 10(23): 8284-8290
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8284
Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
Tian-Tian Xuan, Guang-Yi Li, Si-Bo Meng, Zhan-Mei Wang, Lin-Li Qu
Tian-Tian Xuan, Si-Bo Meng, Zhan-Mei Wang, Lin-Li Qu, Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao 266035, Shandong Province, China
Guang-Yi Li, Department of Respiratory, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao 266035, Shandong Province, China
Author contributions: Xu TT and Qu LL reviewed the literature and contributed to manuscript drafting; Xu TT, Li GY, Meng SB, and Wang ZM analyzed and interpreted the imaging findings; all authors issued final approval for the version to be submitted.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest related to this report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lin-Li Qu, MD, PhD, Chief Doctor, Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, No. 758 Hefei Road, Qingdao 266035, Shandong Province, China. qulinli2021@163.com
Received: January 16, 2022
Peer-review started: January 16, 2022
First decision: March 16, 2022
Revised: April 12, 2022
Accepted: June 21, 2022
Article in press: June 21, 2022
Published online: August 16, 2022
Processing time: 197 Days and 6.3 Hours
Core Tip

Core Tip: A patient with stage IIIB pleural mesothelioma received second-line treatment with a combination of pembrolizumab, bevacizumab and chemotherapy following standard chemotherapy, and achieved partial response after four cycles, with progression-free survival of 5 mo.